Inoperable RCC: stereotactic ablative body radiotherapy shows promise

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Stereotactic ablative body radiotherapy (SABR) delivered encouraging cancer control, functional preservation and early survival outcomes in patients with small and large primary inoperable renal cell carcinoma (RCC). 
  • Treatment was well tolerated. 

Why this matters

  • Age and comorbidities preclude some patients from surgical resection. 
  • Nonsurgical definitive treatment options are limited. 
  • SABR is a well-established noninvasive option for lung, liver, and spinal cancers. 
  • There is a paucity of prospective data to support routine adoption of SABR for primary inoperable RCC.
  • These findings also suggest baseline neutrophil to lymphocyte (N/L) ratio may predict response in RCC.

Study design

  • Study evaluated SABR in 37 inoperable patients with RCC.
  • For primary RCC <5 cm, 26 Gy, and for RCC ≥5 cm, 42 Gy in 3 fractions was delivered.
  • Funding: CASS Science and Medicine Grant; Royal Au...